Discovery of potent heat shock protein 90 (Hsp90) inhibitors: structure-based virtual screening, molecular dynamics simulation, and biological evaluation.

Autor: Xu, Yonghua¹ (AUTHOR), Zou, Yunting² (AUTHOR), Zhou, Shasha¹ (AUTHOR), Niu, Miao-Miao² (AUTHOR), Zhang, Yan³ (AUTHOR), Li, Jindong³ (AUTHOR) warm4455@163.com, Xu, Zhen³ (AUTHOR) internxu90@163.com, Yang, Li³ (AUTHOR) proyangli@163.com

Publikováno v: Journal of Enzyme Inhibition & Medicinal Chemistry. Dec2023, Vol. 38 Issue 1, p1-10. 10p.

IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.

Autor: Grassian AR; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Parker SJ; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Davidson SM; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Divakaruni AS; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Green CR; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Zhang X; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Slocum KL; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Pu M; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Lin F; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Vickers C; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Joud-Caldwell C; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Chung F; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Yin H; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Handly ED; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Straub C; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Growney JD; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Vander Heiden MG; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, CaliforniaAuthors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Murphy AN; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California., Pagliarini R; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California cmetallo@ucsd.edu raymond.pagliarini@novartis.com., Metallo CM; Authors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, CaliforniaAuthors' Affiliations: Novartis Institutes for Biomedical Research; Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of Bioengineering and Pharmacology; and Moores Cancer Center, University of California, San Diego, La Jolla, California cmetallo@ucsd.edu raymond.pagliarini@novartis.com.

Publikováno v: Cancer research [Cancer Res] 2014 Jun 15; Vol. 74 (12), pp. 3317-31. Date of Electronic Publication: 2014 Apr 22.

Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.

Autor: Scaltriti M; Medical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Serra V, Normant E, Guzman M, Rodriguez O, Lim AR, Slocum KL, West KA, Rodriguez V, Prudkin L, Jimenez J, Aura C, Baselga J

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2011 May; Vol. 10 (5), pp. 817-24. Date of Electronic Publication: 2011 Mar 07.

ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib.

Autor: Jikui Guan, Tzu-Po Chuang, Vikström, Anders, Palmer, Ruth H., Hallberg, Bengt

Publikováno v: Frontiers in Oncology; 2024, p1-13, 13p

Merlin regulates signaling events at the nexus of development and cancer.

Autor: Mota, Mateus¹ (AUTHOR), Shevde, Lalita A.^1,2 (AUTHOR) lalitasamant@uabmc.edu

Publikováno v: Cell Communication & Signaling. 4/16/2020, Vol. 18 Issue 1, p1-8. 8p.